Navigation Links
Our Lady of Lourdes Medical Center & The Heart House Participating in Research Study Using Adult Stem Cells for Chronic Cardiac Condition
Date:6/12/2013

Camden, New Jersey (PRWEB) June 12, 2013

Our Lady of Lourdes Medical Center and The Heart House are participating in a clinical study to determine whether a patient’s own (autologous), adult, stem cells are safe and can relieve chronic chest pain caused by coronary artery disease, as well as increase their ability to walk/exercise.

The RENEW study, sponsored by Baxter Healthcare Corporation and endorsed by the FDA to support a Biologic License Application for investigational CD34+ cell therapy, is a Phase III clinical trial to test the safety and efficacy of CD34+ stem cells. The study is being conducted at only 50 sites in North America and will involve approximately 440 patients.

The Principal Investigator, Vijay Verma, MD, FACC, and Sub-Investigator Andrew Zinn, MD, both interventional cardiologists with Cardiovascular Associates of the Delaware Valley (The Heart House), performed the first procedure at Our Lady of Lourdes Medical Center on April 25, 2013. The patient suffers from severe refractory angina, with two of the three arteries that supply oxygen to the heart completely blocked and is unable to undergo conventional revascularization.

“The patient suffers chest pain every day due to the blockages,” said Dr. Verma. “She has exhausted all other optimal therapies, including angioplasty, bypass surgery and enhanced external counter pulsation (EECP) to relieve the persistent chest pain.”

Patients enrolled in the study are randomly assigned to undergo the procedure or receive the standard of care. Patients in the procedure group are blindly randomized to receive either the stem cells or a placebo.

Forty-eight hours prior to the procedure, Dr. Verma conducted Apheresis procedure to selectively withdraw cells from the patient’s bloodstream. These cells were sent to a special lab where CD34+ cells were extracted and sent back to the hospital for injection into the patient’s heart. Derived from bone marrow, CD34+ cells are comprised of endothelial progenitor cells, which may be able to regenerate heart tissue and develop into new blood vessels. Previous Phase I & Phase II clinical trials have shown that the administration of the CD34+ cells were safe, and a reduction in chest pain and increased ability to exercise was noted in people with myocardial ischemia, or lack of oxygen flow to the heart tissue.

During the nearly four-hour procedure, Dr. Verma and his team created an electrical map of the patient’s heart to locate the damaged area they believed might be causing the chest pain. Using a catheter threaded through the patient’s groin area to the heart, Dr. Verma injected the patient’s CD34+ stem cells into areas of heart muscle with poor blood circulation. Neither Dr. Verma nor the patient knows if the stem cells or a placebo were injected until after the trial is completed and data has been obtained and evaluated.

“We will follow her for the next two years to see whether the injections improve her chest pain and her tolerance to exercise,” said Dr. Verma.

To learn if you are eligible to participate in the study, visit http://www.renewstudy.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10825425.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lourdes Doctors Urge Testing During Hepatitis Awareness Month
2. Lourdes Specialty Hospital Offers Unique Treatment Option for Medically Complex Patients with Hyperbaric Oxygen Therapy
3. Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend
4. Physician Groups Call for Fewer Medical Tests
5. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
6. CAM therapy combined with conventional medical care may improve treatment of lower back pain
7. Image share project gives patients and physicians anytime, anywhere access to medical images
8. Researchers determine vitamin D blood level for reducing major medical risks in older adults
9. Biomedical researchers receive Hartwell Foundation awards
10. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
11. Fitness in Middle Age Lowers Medical Costs Later: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Sam & Associates Insurance Agency, ... and related services to residents of the region, is embarking on a charity ... and wild lands. , Endangered Species International is committed to ending the anthropogenic ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... California and Nevada and LABS, Inc., announced the future opening of a CLIA ... screening and serology testing used to determine the suitability of potential organ ...
(Date:3/22/2017)... FL (PRWEB) , ... March 22, 2017 , ... An ... mosquitoes could occasionally transmit HIV, reports Leslie Norins, MD, PhD. He says ... cases of domestically transmitted Zika virus and in new infections with HIV. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, ... therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that ... treatment of non-small cell lung cancer and small cell lung cancer. , Throughout ...
(Date:3/22/2017)... Oklahoma City, OK (PRWEB) , ... March 22, ... ... firm offering insurance and financial planning services to regional families and business owners, ... provide meaningful support to young people in the area. , A growing number ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Respiratory care devices Market is ... next decade to reach approximately $38.27 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/22/2017)... NEW YORK , March 22, 2017 /PRNewswire/ ... pharmaceutical industry, Chinese pharmaceutical packaging market size increased ... during 2010-2016. From 2017 to 2021, the market ... 10% and is expected to outnumber RMB140 billion ... two-child policy, the rapid development of biological agents ...
(Date:3/22/2017)... FALLS, N.J. , March 22, 2017  CANTEL MEDICAL ... Jorgen B. Hansen , President and CEO, will be presenting ... Conference at the Westin Grand Central Hotel in ... Wednesday, April 5, 2017 at 3:00 p.m. ET. In addition, ... day. A live audio webcast will be ...
Breaking Medicine Technology: